371 related articles for article (PubMed ID: 20735851)
1. Engineering of N. benthamiana L. plants for production of N-acetylgalactosamine-glycosylated proteins--towards development of a plant-based platform for production of protein therapeutics with mucin type O-glycosylation.
Daskalova SM; Radder JE; Cichacz ZA; Olsen SH; Tsaprailis G; Mason H; Lopez LC
BMC Biotechnol; 2010 Aug; 10():62. PubMed ID: 20735851
[TBL] [Abstract][Full Text] [Related]
2. Engineering mammalian mucin-type O-glycosylation in plants.
Yang Z; Drew DP; Jørgensen B; Mandel U; Bach SS; Ulvskov P; Levery SB; Bennett EP; Clausen H; Petersen BL
J Biol Chem; 2012 Apr; 287(15):11911-23. PubMed ID: 22334671
[TBL] [Abstract][Full Text] [Related]
3. High level in vivo mucin-type glycosylation in Escherichia coli.
Mueller P; Gauttam R; Raab N; Handrick R; Wahl C; Leptihn S; Zorn M; Kussmaul M; Scheffold M; Eikmanns B; Elling L; Gaisser S
Microb Cell Fact; 2018 Oct; 17(1):168. PubMed ID: 30367634
[TBL] [Abstract][Full Text] [Related]
4. Toward stable genetic engineering of human O-glycosylation in plants.
Yang Z; Bennett EP; Jørgensen B; Drew DP; Arigi E; Mandel U; Ulvskov P; Levery SB; Clausen H; Petersen BL
Plant Physiol; 2012 Sep; 160(1):450-63. PubMed ID: 22791304
[TBL] [Abstract][Full Text] [Related]
5. Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-Acetylgalactosamine:Peptide N-acetylgalactosaminyltransferases. site-specific glycosylation of MUC1 repeat peptide influences the substrate qualities at adjacent or distant Ser/Thr positions.
Hanisch FG; Müller S; Hassan H; Clausen H; Zachara N; Gooley AA; Paulsen H; Alving K; Peter-Katalinic J
J Biol Chem; 1999 Apr; 274(15):9946-54. PubMed ID: 10187769
[TBL] [Abstract][Full Text] [Related]
6. An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
Hashimoto R; Fujitani N; Takegawa Y; Kurogochi M; Matsushita T; Naruchi K; Ohyabu N; Hinou H; Gao XD; Manri N; Satake H; Kaneko A; Sakamoto T; Nishimura S
Chemistry; 2011 Feb; 17(8):2393-404. PubMed ID: 21264968
[TBL] [Abstract][Full Text] [Related]
7. Mucin-type O-glycosylation in helminth parasites from major taxonomic groups: evidence for widespread distribution of the Tn antigen (GalNAc-Ser/Thr) and identification of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase activity.
Casaravilla C; Freire T; Malgor R; Medeiros A; Osinaga E; Carmona C
J Parasitol; 2003 Aug; 89(4):709-14. PubMed ID: 14533679
[TBL] [Abstract][Full Text] [Related]
8. Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat.
Bennett EP; Hassan H; Mandel U; Mirgorodskaya E; Roepstorff P; Burchell J; Taylor-Papadimitriou J; Hollingsworth MA; Merkx G; van Kessel AG; Eiberg H; Steffensen R; Clausen H
J Biol Chem; 1998 Nov; 273(46):30472-81. PubMed ID: 9804815
[TBL] [Abstract][Full Text] [Related]
9. Engineering of sialylated mucin-type O-glycosylation in plants.
Castilho A; Neumann L; Daskalova S; Mason HS; Steinkellner H; Altmann F; Strasser R
J Biol Chem; 2012 Oct; 287(43):36518-26. PubMed ID: 22948156
[TBL] [Abstract][Full Text] [Related]
10. Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation.
Daniel EJP; Las Rivas M; Lira-Navarrete E; García-García A; Hurtado-Guerrero R; Clausen H; Gerken TA
Glycobiology; 2020 Oct; 30(11):910-922. PubMed ID: 32304323
[TBL] [Abstract][Full Text] [Related]
11. Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines.
Marcos NT; Cruz A; Silva F; Almeida R; David L; Mandel U; Clausen H; Von Mensdorff-Pouilly S; Reis CA
J Histochem Cytochem; 2003 Jun; 51(6):761-71. PubMed ID: 12754287
[TBL] [Abstract][Full Text] [Related]
12. Mucin core O-glycosylation is modulated by neighboring residue glycosylation status. Kinetic modeling of the site-specific glycosylation of the apo-porcine submaxillary mucin tandem repeat by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases T1 and T2.
Gerken TA; Zhang J; Levine J; Elhammer A
J Biol Chem; 2002 Dec; 277(51):49850-62. PubMed ID: 12397077
[TBL] [Abstract][Full Text] [Related]
13. Unexpected tolerance of glycosylation by UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase revealed by electron capture dissociation mass spectrometry: carbohydrate as potential protective groups.
Yoshimura Y; Matsushita T; Fujitani N; Takegawa Y; Fujihira H; Naruchi K; Gao XD; Manri N; Sakamoto T; Kato K; Hinou H; Nishimura S
Biochemistry; 2010 Jul; 49(28):5929-41. PubMed ID: 20540529
[TBL] [Abstract][Full Text] [Related]
14. Site-specific O-glycosylation of N-terminal serine residues by polypeptide GalNAc-transferase 2 modulates human δ-opioid receptor turnover at the plasma membrane.
Lackman JJ; Goth CK; Halim A; Vakhrushev SY; Clausen H; Petäjä-Repo UE
Cell Signal; 2018 Jan; 42():184-193. PubMed ID: 29097258
[TBL] [Abstract][Full Text] [Related]
15. High density O-glycosylation of the MUC2 tandem repeat unit by N-acetylgalactosaminyltransferase-3 in colonic adenocarcinoma extracts.
Inoue M; Takahashi S; Yamashina I; Kaibori M; Okumura T; Kamiyama Y; Vichier-Guerre S; Cantacuzène D; Nakada H
Cancer Res; 2001 Feb; 61(3):950-6. PubMed ID: 11221889
[TBL] [Abstract][Full Text] [Related]
16. Glycopeptide-preferring polypeptide GalNAc transferase 10 (ppGalNAc T10), involved in mucin-type O-glycosylation, has a unique GalNAc-O-Ser/Thr-binding site in its catalytic domain not found in ppGalNAc T1 or T2.
Perrine CL; Ganguli A; Wu P; Bertozzi CR; Fritz TA; Raman J; Tabak LA; Gerken TA
J Biol Chem; 2009 Jul; 284(30):20387-97. PubMed ID: 19460755
[TBL] [Abstract][Full Text] [Related]
17. The GalNAc-T Activation Pathway (GALA) is not a general mechanism for regulating mucin-type O-glycosylation.
Herbomel GG; Rojas RE; Tran DT; Ajinkya M; Beck L; Tabak LA
PLoS One; 2017; 12(7):e0179241. PubMed ID: 28719662
[TBL] [Abstract][Full Text] [Related]
18. Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen.
Zhang Y; Iwasaki H; Wang H; Kudo T; Kalka TB; Hennet T; Kubota T; Cheng L; Inaba N; Gotoh M; Togayachi A; Guo J; Hisatomi H; Nakajima K; Nishihara S; Nakamura M; Marth JD; Narimatsu H
J Biol Chem; 2003 Jan; 278(1):573-84. PubMed ID: 12407114
[TBL] [Abstract][Full Text] [Related]
19. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3.
Wandall HH; Hassan H; Mirgorodskaya E; Kristensen AK; Roepstorff P; Bennett EP; Nielsen PA; Hollingsworth MA; Burchell J; Taylor-Papadimitriou J; Clausen H
J Biol Chem; 1997 Sep; 272(38):23503-14. PubMed ID: 9295285
[TBL] [Abstract][Full Text] [Related]
20. Identification of common and unique peptide substrate preferences for the UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases T1 and T2 derived from oriented random peptide substrates.
Gerken TA; Raman J; Fritz TA; Jamison O
J Biol Chem; 2006 Oct; 281(43):32403-16. PubMed ID: 16912039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
